Fatime Krasniqi
SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Digklia A, Kollár A, Felber Dietrich D, Kronig M, Britschgi C, Rordorf T, Jörger M, Krasniqi F, Metaxas Y, Colombo I, Ribi K, Rothermundt C. SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial. Eur J Cancer 2023; 197:113470.
Dec 9, 2023SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Dec 9, 2023Eur J Cancer 2023; 197:113470
Digklia Antonia, Kollár Attila, Felber Dietrich Denise, Kronig M N, Britschgi Christian, Rordorf Tamara, Jörger Markus, Krasniqi Fatime, Metaxas Yannis, Colombo Ilaria, Ribi Karin, Rothermundt Christian
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Blood Adv 2022; 6:3911-3920.
Jul 12, 2022SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Jul 12, 2022Blood Adv 2022; 6:3911-3920
Stathis Anastasios, Mey Ulrich, Schär Sämi, Hitz Felicitas, Pott Christiane, Mach Nicolas, Krasniqi Fatime, Novak Urban, Schmidt Christian, Hohloch Karin, Kienle Dirk, Hess Dagmar, Moccia Alden A, Unterhalt Michael, Eckhardt Katrin, Hayoz Stefanie, Forestieri Gabriela, Rossi Davide, Dirnhofer Stefan, Ceriani Luca, Sartori Giulio, Bertoni Francesco, Buske Christian, Zucca Emanuele, Hiddemann Wolfgang
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
Zucca E, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei S, Ghielmini M, Kimby E, Novak U, Lohri A, Ferreri A, Rondeau S, Vanazzi A, Østenstad B, Mey U, Rauch D, Wahlin B, Hitz F, Hernberg M, Johansson A, de Nully Brown P, Hagberg H, Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood 2019; 134:353-362.
May 17, 2019Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
May 17, 2019Blood 2019; 134:353-362
Zucca Emanuele, Zander Thilo, Bersvendsen Hanne, Bargetzi Mario, Mingrone Walter, Krasniqi Fatime, Dirnhofer Stefan, Hayoz Stefanie, Hawle Hanne, Vilei Simona Berardi, Ghielmini Michele, Kimby Eva, Novak Urban, Lohri Andreas, Ferreri Andrés J M, Rondeau Stephanie, Vanazzi Anna, Østenstad Bjørn, Mey Ulrich J M, Rauch Daniel, Wahlin Björn E, Hitz Felicitas, Hernberg Micaela, Johansson Ann-Sofie, de Nully Brown Peter, Hagberg Hans, Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
Hitz F, Rondeau S, Berardi Vilei S, Eckhardt K, Enoiu M, Rothermundt C, Schmidt A, Krasniqi F, Mach N, Caspar C, Samaras P, Cairoli A, Fischer N, Pabst T, Zucca E, Mey U. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. Br J Haematol 2016
Mar 28, 2016Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
Mar 28, 2016Br J Haematol 2016
Hitz Felicitas, Rondeau Stephanie, Berardi Vilei Simona, Eckhardt Katrin, Enoiu Milica, Rothermundt Christian, Schmidt Adrian, Krasniqi Fatime, Mach Nicolas, Caspar Clemens B, Samaras Panagiotis, Cairoli Anne, Fischer Natalie, Pabst Thomas, Zucca Emanuele, Mey Ulrich
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
Mamot C, Zucca E, Dirnhofer S, Rusterholz C, Biaggi C, Samarin A, Hany T, Gigli F, Krasniqi F, Bargetzi M, Pless M, Mey U, Driessen C, Pabst T, Renner C, Hitz F, Klingbiel D, Martinelli G. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). J Clin Oncol 2015; 33:2523-9.
Jul 6, 2015Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
Jul 6, 2015J Clin Oncol 2015; 33:2523-9
Mamot Christoph, Zucca Emanuele, Dirnhofer Stephan, Rusterholz Corinne, Biaggi Christine, Samarin Andrei, Hany Thomas, Gigli Federica, Krasniqi Fatime, Bargetzi Mario, Pless Miklos, Mey Ulrich, Driessen Christoph, Pabst Thomas, Renner Christoph, Hitz Felicitas, Klingbiel Dirk, Martinelli Giovanni